Document And Entity Information
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Note To Financial Statement Details Textual
Convertible note payable, net of current portion as of June 30, 2025
Significant Accounting Policies
Note 3 - Summary of Significant Accounting Policies
Note 4 - Prepaid Expense and Other Current Assets
nrxp_PaymentForLicenseAgreementMaintenanceFee
Payment for License Agreement, Maintenance Fee
The amount of cash paid for license agreement maintenance fee during the current period.
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Note 5 - Accrued and Other Current Liabilities
Note 8 - Commitments and Contingencies
Hope Therapeutics, Inc. [Member]
Pertains to Hope Therapeutics, Inc.
Note 9 - Equity
Note 10 - Stock-based Compensation
Note 11 - Fair Value Measurements
Note 12 - Segment Reporting
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum
Income Tax Disclosure [Text Block]
Note 3 - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details)
Refund liability (see Note 6)
Customer Refund Liability, Current
Consideration Warrants [Member]
Pertains to consideration warrants.
Note 4 - Prepaid Expense and Other Current Assets - Schedule of Prepaid Expense and Other Current Assets (Details)
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum
Note 5 - Accrued and Other Current Liabilities - Schedule of Accrued and Other Current Liabilities (Details)
Note 8 - Commitments and Contingencies - Schedule of Milestone Payments (Details)
nrxp_ClassOfWarrantOrRightExercisePricePercentageOfClosingPrice
Class of Warrant or Right, Exercise Price, Percentage of Closing Price
Pertains to percentage of closing price.
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum
us-gaap_LiabilitiesCurrent
Total current liabilities
Note 9 - Equity - Schedule of Warrants (Details)
Note 10 - Stock-based Compensation - Schedule of Stock Options (Details)
Note 10 - Stock-based Compensation - Schedule of Restricted Stock Awards (Details)
Note 10 - Stock-based Compensation - Schedule of Stock-based compensation (Details)
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term (Year)
Note 11 - Fair Value Measurements - Schedule of Assets and Liabilities on A Recurring Basis (Details)
Note 11 - Fair Value Measurements - Schedule of Significant Inputs (Details)
Note 11 - Fair Value Measurements - Schedule of Level 3 Fair Value Changes (Details)
Note 12 - Segment Reporting - Reconciliation of Loss From Operations to Total Loss (Details)
Note 12 - Segment Reporting - Long-lived Assets (Details)
Notes To Financial Statements
Notes To Financial Statements [Abstract]
Share-Based Payment Arrangement, Option, Activity [Table Text Block]
Risks and Uncertainties [Policy Text Block]
The disclosure of the entity's policy regarding risks and uncertainties.
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)
Common Stock and Warrant Issuance [Member]
Relating to common stock and warrant issuance.
us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
Business Combination, Voting Equity Interest Acquired, Percentage
Vested, weighted average grant date fair value (in dollars per share)
Warrant liabilities
Forfeited, weighted average grant date fair value (in dollars per share)
Prepaid Expenses and Other Current Assets [Text Block]
The entire disclosure regarding prepaid expenses and other current assets.
Unvested, weighted average grant date fair value (in dollars per share)
Settlement expense
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
Forfeited (in shares)
ATM Offering [Member]
Relating to ATM offering.
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
Balance (unvested) (in shares)
Balance (unvested) (in shares)
Granted (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)
Warrants [Member]
Relating to warrants.
nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodGrantDateFairValue
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Grant Date Fair Value
The fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
Vested (in shares)
Options vested and exercisable, weighted average remaining contractual term (Year)
Options vested and exercisable (in shares)
Nonvested Restricted Stock Shares Activity [Table Text Block]
Options vested and exercisable, weighted average exercise price (in dollars per share)
Options vested and exercisable, aggregate intrinsic value
us-gaap_ProceedsFromDebtNetOfIssuanceCosts
Proceeds from Debt, Net of Issuance Costs
Insurance loan payable
Milestone payment
License Agreement, Milestone Payment
Represents the milestone payment for a license agreement.
Fair value of warrants (in dollars per share)
Represents the fair value of an individual warrant or right.
Convertible note payable and accrued interest – short term
Outstanding, weighted average remaining contractual term (Year)
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
Alvogen and Lotus Warrants [Member]
Relating to Alvogen and Lotus warrants.
Outstanding, aggregate intrinsic value
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
Alvogen Licensing Agreement [Member]
Relating to Alvogen licensing agreement.
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share)
Outstanding, weighted average exercise price (in dollars per share)
Outstanding, weighted average exercise price (in dollars per share)
Convertible note payable - current portion as of June 30, 2025
Forfeited/Expire, weighted average exercise price (in dollars per share)
Options granted, weighted average exercise price (in dollars per share)
nrxp_GainLossOnConvertibleDebtRedemption
Gain (Loss) on Convertible Debt Redemption
Loss on convertible note conversions
Loss on convertible note conversions
The amount of gain (loss) on convertible debt redemption.
Employee costs
us-gaap_ForeignCurrencyExchangeRateRemeasurement1
Foreign Currency Exchange Rate, Remeasurement
nrxp_ConsultingAgreementAnnualPayment
Consulting Agreement, Annual Payment
Represents the annual payment of a consulting agreement.
nrxp_ConsultingAgreementPerformanceBonusTargetValue
Consulting Agreement, Performance Bonus, Target Value
Represents the target performance value of a bonus on a consulting agreement.
nrxp_ConsultingAgreementMonthlyPayment
Consulting Agreement, Monthly Payment
Represents the monthly payment of a consulting agreement.
Accounts payable
Accounts Payable, Current
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)
Outstanding, balance (in shares)
Outstanding, balance (in shares)
Unrestricted Upon New Drug Approval Date [member]
Relating to unrestricted upon New Drug Approval Date.
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted (in shares)
Unrestricted Upon New Drug Application Date [Member]
Relating to unrestricted upon New Drug Application Date.
Streetervile Complaint [Member]
Relating to the Streeterville Complaint.
Expense for debt issuance costs due to fair value election on Anson Notes
Debt Issuance Costs
The cash outflow related to the issuance of debt.
us-gaap_AccruedBonusesCurrent
Accrued Bonuses, Current
nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardAnnualPercentageIncreaseInAuthorizedShares
Share-Based Compensation Arrangement by Share-Based Payment Award, Annual Percentage Increase in Authorized Shares
Represents the annual percentage increase in authorized shares for a share based compensation arrangement.
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
Outstanding, Forfeited/Expire (in shares)
Other accrued expense
us-gaap_PolicyTextBlockAbstract
Accounting Policies
Neuro Rx [Member]
Relating to Neuro Rx.
nrxp_DebtInstrumentNumberOfTranches
Debt Instrument, Number of Tranches
The number of tranches to be received as part of a purchase agreement.
Products Covered By Licensed Patents [Member]
Relating to products covered by licensed patents.
Sarah Herzog Memorial Hospital License Agreement [Member]
Relating to Sarah Herzog Memorial Hospital License Agreement.
Exclusive License Agreement [Member]
Relating to an exclusive license agreement.
nrxp_EquityOfferingMaximumOfferingAmount
Equity Offering, Maximum Offering Amount
Maximum value of company's equity authorized for issuance under equity offering.
Products Covered by Valid Claims [Member]
Relating to products covered by valid claims.
nrxp_LicenseAgreementsMilestonePaymentsConditionalReductionPercentage
License Agreements, Milestone Payments, Conditional Reduction Percentage
Represents the conditional reduction percentage for milestone payments.
nrxp_LicenseAgreementMaintenanceFee
License Agreement, Maintenance Fee
Represents the maintenance fee on a license agreement.
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)
Professional services
nrxp_RoyaltyPercentage
Royalty Percentage
Represents the percentage of revenue that a royalty is paid on.
Schedule of Milestone Payments [Table Text Block]
Tabular disclosure of milestone payments.
End of Phase II Clinical Trials of Licensed Product [Member]
Relating to End of Phase II Clinical Trials of Licensed Product.
End of Phase I Clinical Trials of Licensed Product [Member]
Relating to End of Phase I Clinical Trials of Licensed Product.
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)
Non-cash investing and financing activities
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)
nrxp_PlacementAgentFeePercentOfGrossProceeds
Placement Agent Fee, Percent of Gross Proceeds
The fee paid to the placement agent expressed as a percentage of gross proceeds.
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)
First Commercial Sale of Licensed Product in U.S. [Member]
Relating to First Commercial Sale of Licensed Product in U.S.
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]
End of Phase III Clinical Trials of Licensed Product [Member]
Relating to End of Phase III Clinical Trials of Licensed Product.
Cash paid for taxes
Annual Revenue Threshold [Member]
Relating to when annual revenues pass a certain threshold.
First Commercial Sale of Licensed Product in Europe [Member]
Relating to First Commercial Sale of Licensed Product in Europe.
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Weighted average common shares outstanding:
Vesting [Axis]
Vesting [Domain]
us-gaap_Assets
Total assets
Supplemental disclosure of cash flow information:
Conversion of Principal Into Common Stock [Member]
Relating to the conversion of principal into common stock.
nrxp_ClassOfWarrantOrRightExercisedDuringPeriod
Class of Warrant or Right, Exercised During Period (in shares)
The number of warrants or rights exercised during period.
Plan Name [Axis]
Conversion of Accrued Interest Into Common Stock [Member]
Relating to the conversion of accrued interest into common stock.
Plan Name [Domain]
Cohen and Associates, LLC [Member]
Relating to Cohen and Associates, LLC.
us-gaap_OperatingLeaseExpense
Operating Lease, Expense
us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)
February Overallotment Option [Member]
Relating to the February Over-allotment Option.
February Underwriting Agreement [Member]
Relating to the February Underwriting Agreement.
nrxp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Fair Value
The grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.
Public Warrants [Member]
Relating to public warrants.
Streeterville Convertible Note [Member]
Represents the Streeterville Convertible Note.
Substitute Warrants [Member]
Relating to substitute warrants.
Lease Contractual Term, Office Space, Rental [Member]
Pertains to the type lease arrangement.
nrxp_PrivatePlacementPremiumPercentage
Private Placement, Premium Percentage
Represents the premium percentage on a private placement.
Patent License [Member]
Pertains to the type of expense.
Stock Issuance to Vendor [Member]
Relating to stock issuance to a vendor.
Anson Warrants Tranche One [Member]
Represents the Anson Warrants issued in Tranche One.
February Warrants [Member]
Relating to February warrants.
Anson First and Third Tranche Notes [Member]
Relating to the Anson first and third tranche notes.
nrxp_ClassOfWarrantsOrRightsWeightedAverageExercisePrice
Outstanding, weighted average exercise price (in dollars per share)
Outstanding, weighted average exercise price (in dollars per share)
Represents the weighted average exercise price for warrants or rights.
Outstanding, weighted average remaining contractual term (Year)
Represents the weighted average remaining term for warrants or rights.
Issued (in shares)
Represents the number of warrants or rights issued during the period.
Outstanding, aggregate intrinsic value
Represents the aggregate intrinsic value of warrants or rights.
February Underwriter Warrants [Member]
Relating to the February underwriter warrants.
Private Placement Warrants [Member]
Relating to private placement warrants.
Share-Based Payment Arrangement [Text Block]
nrxp_ClassOfWarrantOrRightBeneficialOwnershipLimitation
Class of Warrant or Right, Beneficial Ownership Limitation
Represents the beneficial ownership limitation on warrants or rights.
Underwriter Overallotment Warrants [Member]
Relating to the underwriter over-allotment warrants.
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
April Overallotment Agreement [Member]
Relating to the April Over-Allotment Agreement.
April Underwriter Agreement [Member]
Relating to the April Underwriter Agreement.
Expired (in shares)
Represents the number of warrants or rights expired during the period.
Conversion of Principal and Interest Into Common Stock [Member]
Relating to the conversion of principal and interest into common stock.
Award Type [Domain]
nrxp_DebtInstrumentOriginalIssuanceDiscount
Debt Instrument, Original Issuance Discount
Amount of original issuance discount expressed as a percentage.
nrxp_DebtInstrumentInterestRateInEventOfDefault
Debt Instrument, Interest Rate in Event of Default
Contractual interest rate for funds borrowed, under the debt agreement, in the event of default.
nrxp_ClassOfWarrantOrRightSecuritiesCalledByWarrantsOrRightsPercentageOfPrincipalDividedByVwap
Class of Warrant or Right, Securities Called by Warrants or Rights, Percentage of Principal Divided by VWAP
The number of securities into which the class of warrant or right may be converted expressed as a percentage of the principal amount of the notes divided by the WVAP of the Company's common stock.
April Underwriter Warrants [Member]
Relating to the April Underwriter Warrants.
Anson First Tranche Notes [Member]
Represents the Anson First Tranche Notes.
nrxp_FairValueAdjustmentOfConvertibleDebt
Change in fair value of convertible note payable
Represents the fair value adjustment of convertible debt.
Anson Warrants [Member]
Represents the Anson Warrants.
April Overallotment Warrants [Member]
Relating to the April Over-Allotment Warrants.
Award Type [Axis]
Net loss
Net loss
Net loss
Anson Convertible Notes [Member]
Represents the Anson Convertible Notes.
Accrued and other current liabilities
Total accrued and other current liabilities
Amount of expenses incurred but not yet paid nor invoiced within one operating cycle, and liabilities classified as other.
Anson Second Tranche Notes [Member]
Represents the Anson Second Tranche Notes.
Anson Warrants Tranche Two [Member]
Represents Anson Warrants Tranche Two.
Restricted Stock [Member]
Issuance of common stock warrants as offering costs
The fair value of stock issued in noncash financing activities for offering costs.
Share-Based Payment Arrangement, Option [Member]
Warrant [Member]
Initial recognition of issuance of warrants
The initial recognition of the fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Antidilutive Securities [Axis]
Antidilutive Securities, Name [Domain]
Commitments and Contingencies Disclosure [Text Block]
us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
Accumulated depreciation
us-gaap_PropertyPlantAndEquipmentNet
Total equipment
Computers, cost
Long-Term Debt, Type [Axis]
Long-Term Debt, Type [Domain]
Conversion and repayments of principal and interest (shares)
Amount of conversion to shares of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
Net loss per share:
Convertible Debt [Member]
us-gaap_DeferredFinanceCostsGross
Debt Issuance Costs, Gross
us-gaap_RelatedPartyTransactionAmountsOfTransaction
Related Party Transaction, Amounts of Transaction
Related Party Transactions Disclosure [Text Block]
us-gaap_IncomeTaxExpenseBenefit
Income Tax Expense (Benefit)
Accounts payable
us-gaap_IncreaseDecreaseInAccountsPayable
us-gaap_OperatingExpenses
Total operating expenses
us-gaap_DebtInstrumentTerm
Debt Instrument, Term (Month)
General and administrative
Cash and cash equivalents
Cash and Cash Equivalent
us-gaap_DebtInstrumentConvertibleThresholdTradingDays
Debt Instrument, Convertible, Threshold Trading Days
Interest expense
Interest expense
us-gaap_DebtInstrumentConvertibleConversionPrice1
Debt Instrument, Convertible, Conversion Price (in dollars per share)
Stock-based compensation expense
us-gaap_AllocatedShareBasedCompensationExpense
Share-Based Payment Arrangement, Expense
us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger
nrxp_GainLossOnIssuanceOfCommonStock
Gain (Loss) on Issuance of Common Stock
Loss on issuance of the Registered Direct Offering (see Note 9)
Loss on issuance of the Registered Direct Offering
The amount of gain/loss on the issuance of common stock.
Fair value adjustment through earnings
Loss (gain) upon re-measurement
nrxp_GainLossOnConsiderationSharesAndWarrants
Gain (Loss) on Consideration Shares and Warrants
Loss on Consideration Shares and Warrants (see Note 9)
Loss on Consideration Shares and Warrants
The amount of gain/loss on consideration shares and warrants.
Amendment Flag
Anson, Third Tranche Notes [Member]
Represents information pertaining to the third tranche notes for Anson.
City Area Code
Use of Estimates, Policy [Policy Text Block]
New Accounting Pronouncements, Policy [Policy Text Block]
Measurement Input Cost of Debt [Member]
Measurement input using the cost of debt.
nrxp_LicenseAgreementCumulativePayments
License Agreement, Cumulative Payments
The cumulative amount paid for the licensing agreement.
Anson Warrants, Tranche Three [Member]
Represents information pertaining to Anson warrants three.
Accrued expense and other liabilities
Issuance of shares related to reverse stock split (in shares)
us-gaap_SharesOutstanding
Balance (in shares)
Balance (in shares)
Common stock, outstanding (in shares)
Preferred stock, outstanding (in shares)
Preferred Stock, Shares Outstanding (in shares)
Warrants Issued for Alvogen Agreement Amendment [Member]
Represents the warrants issued for the Alvogen agreement amendment.
Registered Direct Offering [Member]
Represents information pertaining to the registered direct offering.
NRX-100 [Member]
Represents NRX-100.
Current Fiscal Year End Date
us-gaap_DebtInstrumentInterestRateStatedPercentage
Debt Instrument, Interest Rate, Stated Percentage
us-gaap_DebtInstrumentInterestRateEffectivePercentage
Debt Instrument, Interest Rate, Effective Percentage
us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
Prepaid expense and other assets
Consideration Shares [Member]
Represents information pertaining to consideration shares.
Conversion of Principal and Interest into Consideration Warrants [Member]
Represents information pertaining to the conversion of principal and interest into consideration warrants.
Anson Note [Member]
Represents the Anson Note
Conversion of Principal and Interest into Consideration Shares [Member]
Represents information pertaining to the conversion of principal and interest into consideration shares.
Document Fiscal Period Focus
Amortization of deferred offering costs to additional paid-in-capital
The value of warrants issued as a result of VWAP adjustments.
Document Fiscal Year Focus
nrxp_ExpectedSavings
Expected Savings
Amount of expected savings.
Document Period End Date
Entity File Number
Entity Emerging Growth Company
us-gaap_DebtInstrumentFaceAmount
Debt Instrument, Face Amount
Document Type
Interim Period, Costs Not Allocable [Domain]
Entity Small Business
Entity Shell Company
Document Information [Line Items]
Document Information [Table]
Nature of Expense [Axis]
us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
Balance
Fair value of Anson Notes as of March 31, 2025
nrxp_LongtermDebtPrincipalOnly
Long-Term Debt, Principal Only
The portion of long-term debt representing the amount of principal still left to be repaid.
Entity Filer Category
Debt Instrument [Axis]
Consent and Waiver Agreement [Member]
Represents the Consent and Waiver Agreement ("CWA").
Entity Current Reporting Status
Debt Instrument, Name [Domain]
Fair value of Anson III Note at issuance
us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued
Adjustments to Additional Paid in Capital, Warrant Issued
Fair value allocation of warrants issued with Registered Direct offering
Stock-based compensation
Options granted, weighted average remaining contractual term (Year)
Weighted average remaining contractual term for option awards granted during the period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
Entity Tax Identification Number
Entity Central Index Key
Entity Registrant Name
Liability Class [Axis]
nrxp_GainLossOnIssuanceOfRegisteredDirectOffering
Loss on issuance of Registered Direct Offering
The amount of gain(loss) on issuance of a registered direct offering.
Fair Value by Liability Class [Domain]
Entity [Domain]
Legal Entity [Axis]
Entity Address, Address Line One
Offering costs
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
ecd_NonRule10b51ArrTrmntdFlag
Non-Rule 10b5-1 Arrangement Terminated [Flag]
Entity Address, City or Town
ecd_Rule10b51ArrTrmntdFlag
Rule 10b5-1 Arrangement Terminated [Flag]
ecd_Rule10b51ArrAdoptedFlag
Rule 10b5-1 Arrangement Adopted [Flag]
Entity Address, Postal Zip Code
Entity Address, State or Province
ecd_NonRule10b51ArrAdoptedFlag
Non-Rule 10b5-1 Arrangement Adopted [Flag]
Material Terms of Trading Arrangement [Text Block]
Entity Common Stock, Shares Outstanding
Trading Arrangements, by Individual [Table]
Shares issued as conversion of principal and interest for convertible note (in shares)
Trading Symbol
Shares issued as conversion of principal and interest for convertible note
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
Conversion of Series A preferred stock into common stock
Conversion of Series A preferred stock into common stock (in shares)
Local Phone Number
us-gaap_TableTextBlock
Notes Tables
Vesting of restricted stock awards (in shares)
Vesting of restricted stock awards
Related and Nonrelated Parties [Axis]
Related and Nonrelated Parties [Domain]
us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture (in shares)
Outstanding, granted (in shares)
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)
Warrant measurement input
Warrants and Rights Outstanding, Measurement Input
us-gaap_WarrantsAndRightsOutstandingTerm
Warrants and Rights Outstanding, Term (Year)
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Stock issuances, net (in shares)
Stock Issued During Period, Shares, New Issues (in shares)
Shares issued in exchange for services
Stock Issued During Period, Value, Issued for Services
Shares issued in exchange for services (in shares)
Stock Issued During Period, Shares, Issued for Services (in shares)
us-gaap_LiabilitiesAndStockholdersEquity
Total liabilities and stockholders' deficit
us-gaap_CashUninsuredAmount
Cash, Uninsured Amount
Stock issuances, net
Stock Issued During Period, Value, New Issues
Related Party Transaction [Axis]
Related Party Transaction [Domain]
Research and development
Research and Development Expense
Accumulated deficit
Measurement Input, Share Price [Member]
Debt Disclosure [Text Block]
Measurement Input, Price Volatility [Member]
Changes in operating assets and liabilities:
Measurement Input, Risk Free Interest Rate [Member]
us-gaap_DisclosureTextBlockAbstract
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]
Measurement Input, Expected Dividend Rate [Member]
Subsequent Event [Member]
Measurement Input, Expected Term [Member]
Measurement Input, Exercise Price [Member]
Subsequent Event Type [Axis]
Subsequent Event Type [Domain]
Measurement input
Subsequent Events [Text Block]
Measurement Input Type [Axis]
Measurement Input Type [Domain]
Fair Value of Financial Instruments, Policy [Policy Text Block]
Segment Reporting, Policy [Policy Text Block]
Common stock issued in exchange for services
us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims
Change in fair value of warrant liabilities
Fair Value Adjustment of Warrants
Issuance of common stock as principal and interest repayment for convertible notes
Debt Conversion, Converted Instrument, Amount
Other assets
Stock-based compensation
us-gaap_ShareBasedCompensation
us-gaap_DebtConversionConvertedInstrumentSharesIssued1
Debt Conversion, Converted Instrument, Shares Issued (in shares)
Earnings Per Share, Policy [Policy Text Block]
us-gaap_DebtConversionOriginalDebtAmount1
Debt Conversion, Original Debt, Amount
Debt Conversion Description [Axis]
Debt Conversion, Name [Domain]
Operating expense:
Income Tax, Policy [Policy Text Block]
us-gaap_LiabilitiesFairValueAdjustment
Liabilities, Fair Value Adjustment
Research and Development Expense, Policy [Policy Text Block]
Conversion of Series A preferred stock into common stock
us-gaap_ConversionOfStockAmountConverted1
Depreciation expense
us-gaap_ConversionOfStockSharesIssued1
Conversion of Stock, Shares Issued (in shares)
us-gaap_ConversionOfStockSharesConverted1
Conversion of Stock, Shares Converted (in shares)
us-gaap_SharesIssuedPricePerShare
Shares Issued, Price Per Share (in dollars per share)
Stock Conversion Description [Axis]
Conversion of Stock, Name [Domain]
us-gaap_AssetsCurrent
Total current assets
Money Market Account
Share-Based Payment Arrangement [Policy Text Block]
Equity [Text Block]
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]
Common stock, $0.001 par value, 500,000,000 shares authorized; 19,473,588 and 14,591,505 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively
us-gaap_InvestmentOwnedAtFairValue
Investment Owned, Fair Value
Measurement Frequency [Axis]
Adjustments to reconcile net loss to net cash used in operating activities:
Measurement Frequency [Domain]
Fair Value, Recurring [Member]
Common stock, authorized (in shares)
Common Stock, Shares Authorized (in shares)
Common stock, issued (in shares)
Common stock, par value (in dollars per share)
Common Stock, Par or Stated Value Per Share (in dollars per share)
Stockholders' Equity, Policy [Policy Text Block]
Statistical Measurement [Domain]
Maximum [Member]
Minimum [Member]
us-gaap_PaymentsForRoyalties
Payments for Royalties
Ownership [Domain]
Product and Service [Axis]
us-gaap_PaymentsForLegalSettlements
Payments for Legal Settlements
Product and Service [Domain]
Statistical Measurement [Axis]
Deferred Charges, Policy [Policy Text Block]
Litigation Case [Axis]
Litigation Case [Domain]
Debt, Policy [Policy Text Block]
Ownership [Axis]
Preferred stock
Preferred stock, issued (in shares)
Preferred Stock, Shares Issued (in shares)
Cash paid for interest
Other prepaid expense
Preferred stock, authorized (in shares)
Preferred Stock, Shares Authorized (in shares)
Portion at Fair Value Measurement [Member]
Preferred stock, par value (in dollars per share)
Preferred Stock, Par or Stated Value Per Share (in dollars per share)
Estimate of Fair Value Measurement [Member]
Prepaid insurance
us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Revenue from Contract with Customer, Including Assessed Tax
Measurement Basis [Axis]
Fair Value, Inputs, Level 3 [Member]
Fair Value Hierarchy and NAV [Domain]
Fair Value, Inputs, Level 1 [Member]
Reconciliation of Assets from Segment to Consolidated [Table Text Block]
Fair Value Hierarchy and NAV [Axis]
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]
CASH FLOWS FROM OPERATING ACTIVITIES:
Revenue [Policy Text Block]
us-gaap_WarrantsAndRightsOutstanding
Warrants and Rights Outstanding
Statement [Line Items]
us-gaap_NumberOfOperatingSegments
Number of Operating Segments
us-gaap_NumberOfReportableSegments
Number of Reportable Segments
Additional paid-in capital
AOCI Attributable to Parent [Member]
nrxp_StockSubscriptionsReceivableWriteOff
Stock Subscriptions Receivable, Write Off
Write off amount of stock subscriptions receivable during a period of time.
Long-Lived Tangible Asset [Axis]
us-gaap_NonoperatingIncomeExpense
Total other expenses, net
Segment Reporting Disclosure [Text Block]
Long-Lived Tangible Asset [Domain]
Chief Executive Officer [Member]
nrxp_LitigationSettlementPaymentInstallmentTwo
Litigation Settlement, Payment Installment Two
Amount of payment installment two for litigation settlement.
nrxp_LitigationSettlementPaymentInstallmentOne
Litigation Settlement, Payment Installment One
Amount of payment installment one for litigation settlement.
Fair Value Disclosures [Text Block]
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
ASSETS
Private Placement [Member]
us-gaap_InvestmentIncomeInterest
Interest income
Interest income
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
Net increase (decrease) in cash and cash equivalents
us-gaap_Liabilities
Total liabilities
us-gaap_NetCashProvidedByUsedInFinancingActivities
Net cash provided by financing activities
Commitments and Contingencies (Note 8)
Sale of Stock [Axis]
Sale of Stock [Domain]
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]
us-gaap_OperatingIncomeLoss
Loss from operations
Loss from operations
Other (income) expense:
us-gaap_NetCashProvidedByUsedInOperatingActivities
Net cash used in operating activities
Prepaid expenses and other current assets
Total prepaid expense and other current assets
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]
Derivatives, Policy [Policy Text Block]
Consolidation Items [Domain]
Warrant liabilities (Note 9)
Consolidation Items [Axis]
us-gaap_InterestPayableCurrentAndNoncurrent
Interest Payable
us-gaap_PaymentsOfStockIssuanceCosts
Payments of Stock Issuance Costs
Concentration Risk, Credit Risk, Policy [Policy Text Block]
us-gaap_ProceedsFromIssuanceOrSaleOfEquity
Proceeds from Issuance or Sale of Equity
Proceeds from issuance of common stock and warrants issued in private placement, net of issuance costs
Proceeds from Issuance of Private Placement
Retained Earnings [Member]
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Revenue from Contract with Customer, Excluding Assessed Tax
Proceeds from ATM offering, net of offering costs
Proceeds from Issuance of Common Stock
Title and Position [Domain]
Title and Position [Axis]
Consideration Shares issued as a result of repricing (See Note 9) (in shares)
The number of shares issued as a result from the repricing of shares.
Additional Paid-in Capital [Member]
Common Stock [Member]
Preferred Stock [Member]
Consideration Shares issued as a result of repricing (See Note 9)
The value of shares issued from the repricing of shares.
Equity Components [Axis]
Equity Component [Domain]
nrxp_ClassOfWarrantOfRightGrantDateFairValue
Class of Warrant of Right, Grant Date Fair Value
The grant date fair value of the warrants and right issued.
Proceeds from issuance of insurance loan
The cash inflow from insurance loans.
Warrants Other Than Consideration Warrants [Member]
The other than consideration warrants.
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)
Class of Warrant or Right [Axis]
Conversion of Debt to Common Stock [Member]
Represents the conversion of debt.
Class of Warrant or Right [Domain]
us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)
us-gaap_ClassOfWarrantOrRightOutstanding
Class of Warrant or Right, Outstanding (in shares)
Outstanding, balance (in shares)
Outstanding, balance (in shares)
nrxp_AdjustmentsToAdditionalPaidInCapitalAmortizationOfPrepaidOfferingCosts
Amortization of deferred offering costs
Amount of decrease in additional paid in capital (APIC) resulting from the amortization of prepaid offering costs.
us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)
us-gaap_PaymentsOfDebtIssuanceCosts
Expense for debt issuance costs due to fair value election on Anson Notes
us-gaap_RepaymentsOfConvertibleDebt
Repayment of convertible note
Computer Equipment [Member]
Cash and Cash Equivalents, Policy [Policy Text Block]
us-gaap_DebtInstrumentUnamortizedDiscount
Debt Instrument, Unamortized Discount
Document Quarterly Report
Entity Incorporation, State or Country Code
us-gaap_DebtInstrumentCarryingAmount
Long-Term Debt, Gross
General and Administrative Expense [Member]
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]
Document Transition Report
Basis of Accounting, Policy [Policy Text Block]
Entity Interactive Data Current
Related Party [Member]
Security Exchange Name
Title of 12(b) Security
Proceeds from Anson convertible notes, net of OID
Proceeds from Convertible Debt
Series A Convertible Preferred Stock [Member]
Series A preferred stock that may be exchanged into common shares or other types of securities at the owner's option.
Research and Development Expense [Member]
Statement of Income Location, Balance [Axis]
Statement of Income Location, Balance [Domain]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Conversion of Series A Preferred Stock to Common Stock [Member]
The unique name of a noncash or part noncash stock conversion.
Insurance loan payable
nrxp_IncreaseDecreaseInInsuranceLoanPayable
The increase/decrease in insurance loan payable.
Collaborative Arrangement Disclosure [Text Block]
Accrued clinical site costs
Represents accrued clinical site costs.
Warrant issuance costs related to Alvogen termination
The costs related to the contract.
nrxp_RepaymentsOfInsuranceLoans
Repayment of insurance loan
The repayment of insurance loans.
April 2024 Offering [Member]
Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.
us-gaap_SharePrice
Share Price (in dollars per share)
Accrued research and development expense
Carrying value as of the balance sheet date of obligations incurred and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Antidilutive securities (in shares)
Prepaid clinical development costs
Amount of asset related to consideration paid in advance for clinical development that provides economic benefits within a future period of one year or the normal operating cycle, if longer.
The 2021 Omnibus Incentive Plan [Member]
Plan name for share-based payment arrangement.
Statement [Table]
The 2016 Omnibus Incentive Plan [Member]
Plan name for share-based payment arrangement.
Statement of Financial Position [Abstract]
Consultation Agreement with Zachary Javitt [Member]
Information by type of related party transaction.
Basic and diluted (in shares)
Consultation Agreement with Dr. Jonathan Javitt [Member]
Information by type of related party transaction.
Nondesignated Preferred Stock [Member]
The Nondesignated Preferred Stock.
Business Combination [Axis]
Basic and diluted (in dollars per share)
Business Combination [Domain]
NRX Pharmaceuticals, Inc [Member]
Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment.
Statement of Cash Flows [Abstract]
Proceeds from issuance of common stock and warrants, net of issuance costs
The proceeds from issuance of common stock and warrants
Statement of Stockholders' Equity [Abstract]
Lease Contractual Term [Domain]
Contract cost related to Alvogen termination (see Note 6)
The contract costs related to the Alvogen termination.
Lease Contractual Term [Axis]
Glytech License Agreement [Member]
Information by type of related party transaction.
Income Statement [Abstract]
us-gaap_ProceedsFromIssuanceOfDebt
Proceeds from Issuance of Debt
us-gaap_RepaymentsOfDebt
Repayments of Debt
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]
Measurement Input, Probability of Default [Member]
Measurement input using the probability of default.
Issued, weighted average remaining term (Year)
Weighted average remaining contractual term for warrants or rights issued during the period.
Issued, weighted average exercise price (in dollars per share)
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of warrants.
Convertible note default penalty
convertible note default penalties
CASH FLOWS FROM FINANCING ACTIVITIES
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
RD Purchase Agreement [Member]
Pertains to the RD Purchase Agreement.
Convertible note payable and accrued interest (Note 7)
Third Tranche Notes, Warrants [Member]
Pertains to Third Tranche Notes, Warrants.
Third Tranche Notes [Member]
Pertains to the Third Tranche Notes.
Series A Preferred Stock [Member]
us-gaap_StockholdersEquity
Total stockholders’ deficit
Balance
Balance
Class of Stock [Axis]
Class of Stock [Domain]
nrxp_ClassOfWarrantOrRightIssuedInPeriod
Class of Warrant or Right Issued in Period (in shares)
The number of warrants issued.
Operating Segments [Member]
Convertible note payable and accrued interest – long term